This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).
Subject is 18 years of age or older;
Subject is willing to provide written informed consent;
Subject has a diagnosis of a non-hematologic cancer, has tumor in the body, and has either;
residual tumor tissue available for testing by the Sponsor; or
Underwent curative-intent surgery for management of the presently diagnosed tumor, at any time prior to the Baseline Visit.
Underwent targeted or non-targeted chemotherapy, hormone receptor blocking therapy, or radiation therapy prior to the Baseline Visit.
Underwent an invasive procedure (biopsy, surgery, thermal ablation) in the 7 days prior to any blood collection (baseline or follow-up).
Any medical or mental condition that would interfere with the subjects' ability to willingly give written informed consent.